185 related articles for article (PubMed ID: 27009216)
1. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
[TBL] [Abstract][Full Text] [Related]
2. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
3. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
5. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
Li Y; Hickson JA; Ambrosi DJ; Haasch DL; Foster-Duke KD; Eaton LJ; DiGiammarino EL; Panchal SC; Jiang F; Mudd SR; Zhang C; Akella SS; Gao W; Ralston SL; Naumovski L; Gu J; Morgan-Lappe SE
Mol Cancer Ther; 2018 May; 17(5):1039-1050. PubMed ID: 29592882
[TBL] [Abstract][Full Text] [Related]
6. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
7. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
8. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer.
Chiron M; Bagley RG; Pollard J; Mankoo PK; Henry C; Vincent L; Geslin C; Baltes N; Bergstrom DA
Mol Cancer Ther; 2014 Jun; 13(6):1636-44. PubMed ID: 24688047
[TBL] [Abstract][Full Text] [Related]
9. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
Hu W; Lu C; Dong HH; Huang J; Shen DY; Stone RL; Nick AM; Shahzad MM; Mora E; Jennings NB; Lee SJ; Roh JW; Matsuo K; Nishimura M; Goodman BW; Jaffe RB; Langley RR; Deavers MT; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Res; 2011 Sep; 71(18):6030-9. PubMed ID: 21795478
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma.
Kim DY; Choi JA; Koh JY; Yoon YH
J Exp Clin Cancer Res; 2016 Nov; 35(1):171. PubMed ID: 27814771
[TBL] [Abstract][Full Text] [Related]
11. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
[TBL] [Abstract][Full Text] [Related]
12. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
Singh R; Kim WJ; Kim PH; Hong HJ
Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
[TBL] [Abstract][Full Text] [Related]
13. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
14. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
15. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
16. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer.
Wang H; Huang X; Zhang J; Shao N; Chen LO; Ma D; Ji C
Clin Chim Acta; 2014 Sep; 436():243-8. PubMed ID: 24949865
[TBL] [Abstract][Full Text] [Related]
17. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
Steg AD; Katre AA; Goodman B; Han HD; Nick AM; Stone RL; Coleman RL; Alvarez RD; Lopez-Berestein G; Sood AK; Landen CN
Clin Cancer Res; 2011 Sep; 17(17):5674-85. PubMed ID: 21753153
[TBL] [Abstract][Full Text] [Related]
18. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade.
Yamanda S; Ebihara S; Asada M; Okazaki T; Niu K; Ebihara T; Koyanagi A; Yamaguchi N; Yagita H; Arai H
Blood; 2009 Apr; 113(15):3631-9. PubMed ID: 19218547
[TBL] [Abstract][Full Text] [Related]
19. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
20. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
Sun HW; Wu C; Tan HY; Wang QS
Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
